These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35286926)

  • 1. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification.
    Carbone D; Vestuto V; Ferraro MR; Ciaglia T; Pecoraro C; Sommella E; Cascioferro S; Salviati E; Novi S; Tecce MF; Amodio G; Iraci N; Cirrincione G; Campiglia P; Diana P; Bertamino A; Parrino B; Ostacolo C
    Eur J Med Chem; 2022 Apr; 234():114233. PubMed ID: 35286926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
    Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
    PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
    Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
    Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
    Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.
    Duvall B; Zimmermann SC; Gao RD; Thomas AG; Kalčic F; Veeravalli V; Elgogary A; Rais R; Rojas C; Le A; Slusher BS; Tsukamoto T
    Bioorg Med Chem; 2020 Oct; 28(20):115698. PubMed ID: 33069080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
    Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
    Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.
    de Los Santos-Jiménez J; Campos-Sandoval JA; Márquez-Torres C; Urbano-Polo N; Brøndegaard D; Martín-Rufián M; Lobo C; Peñalver A; Gómez-García MC; Martín-Campos J; Cardona C; Castilla L; da Costa Souza F; Cheng T; Segura JA; Alonso FJ; Curi R; Colquhoun A; DeBerardinis RJ; Márquez J; Matés JM
    J Biomed Sci; 2021 Feb; 28(1):14. PubMed ID: 33610185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition.
    Ulanet DB; Couto K; Jha A; Choe S; Wang A; Woo HK; Steadman M; DeLaBarre B; Gross S; Driggers E; Dorsch M; Hurov JB
    PLoS One; 2014; 9(12):e115144. PubMed ID: 25502225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
    Soth MJ; Le K; Di Francesco ME; Hamilton MM; Liu G; Burke JP; Carroll CL; Kovacs JJ; Bardenhagen JP; Bristow CA; Cardozo M; Czako B; de Stanchina E; Feng N; Garvey JR; Gay JP; Do MKG; Greer J; Han M; Harris A; Herrera Z; Huang S; Giuliani V; Jiang Y; Johnson SB; Johnson TA; Kang Z; Leonard PG; Liu Z; McAfoos T; Miller M; Morlacchi P; Mullinax RA; Palmer WS; Pang J; Rogers N; Rudin CM; Shepard HE; Spencer ND; Theroff J; Wu Q; Xu A; Yau JA; Draetta G; Toniatti C; Heffernan TP; Jones P
    J Med Chem; 2020 Nov; 63(21):12957-12977. PubMed ID: 33118821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
    Szeliga M; Albrecht J
    Neurochem Int; 2015 Sep; 88():6-9. PubMed ID: 25529918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Screening Reveals New Glutaminase Inhibitor Molecules.
    E Costa RK; Rodrigues CT; H Campos JC; Paradela LS; Dias MM; Novaes da Silva B; de Valega Negrao CVZ; Gonçalves KA; Ascenção CFR; Adamoski D; Mercaldi GF; Bastos ACS; Batista FAH; Figueira AC; Cordeiro AT; Ambrosio ALB; Guido RVC; Dias SMG
    ACS Pharmacol Transl Sci; 2021 Dec; 4(6):1849-1866. PubMed ID: 34927015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
    Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
    J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutaminase inhibitors: a patent review.
    Wu C; Chen L; Jin S; Li H
    Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic fingerprinting reveals extensive consequences of GLS hyperactivity.
    Rumping L; Pras-Raves ML; Gerrits J; Tang YF; Willemsen MA; Houwen RHJ; van Haaften G; van Hasselt PM; Verhoeven-Duif NM; Jans JJM
    Biochim Biophys Acta Gen Subj; 2020 Mar; 1864(3):129484. PubMed ID: 31734463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Development of Small Molecule Glutaminase Inhibitors.
    Song M; Kim SH; Im CY; Hwang HJ
    Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLS2 is protumorigenic in breast cancers.
    Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
    Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.